Lv6
2640 积分 2024-05-22 加入
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
4个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
7个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
7个月前
已完结
Non-small-cell lung cancer
9个月前
已完结
Top advances of the year: Ovarian cancer
9个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
10个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
10个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
11个月前
已完结
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
1年前
已完结
Glioma
1年前
已完结
皖公网安备34019202002308
